Silverlake Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History

Silverlake Wealth Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$369K	Buy	6,410 +1	+0%	+$57	0.07%	260
2026 Q1	$389K	Sell	6,409 -390	-6%	-$22.7K	0.08%	246
2025 Q4	$367K	Buy	6,799 +957	+16%	+$46K	0.08%	234
2025 Q3	$263K	Buy	5,842 +7	+0.1%	+$327	0.06%	282
2025 Q2	$270K	Buy	5,835 +269	+5%	+$13.2K	0.08%	265
2025 Q1	$339K	Buy	5,566 +3	+0.1%	+$175	0.13%	171
2024 Q4	$315K	Buy	5,563 +2	+0%	+$112	0.12%	184
2024 Q3	$288K	Buy	5,561 +3	+0.1%	+$141	0.11%	210
2024 Q2	$231K	Buy	5,558 +3	+0.1%	+$134	0.09%	239
2024 Q1	$301K	Buy	5,555 +2	+0%	+$102	0.15%	172
2023 Q4	$285K	Sell	5,553 -621	-10%	-$32.6K	0.16%	167
2023 Q3	$358K	Buy	6,174 +33	+0.5%	+$2.02K	0.2%	140
2023 Q2	$393K	Sell	6,141 -28	-0.5%	-$1.88K	0.22%	119
2023 Q1	$428K	Sell	6,169 -1,211	-16%	-$85.4K	0.26%	104
2022 Q4	$531K	Buy	7,380 +4	+0.1%	+$302	0.33%	71
2022 Q3	$524K	Sell	7,376 -3	-0%	-$218	0.36%	73
2022 Q2	$568K	Buy	7,379 +136	+2%	+$10.4K	0.37%	70
2022 Q1	$529K	Buy	7,243 +95	+1%	+$6.38K	0.3%	80
2021 Q4	$446K	Buy	+7,148	New	+$419K	0.24%	107

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Silverlake Wealth Management's BMY Position: Q2 2026 in Review

Silverlake Wealth Management increased its Bristol-Myers Squibb (BMY) stake by 0.02% in Q2 2026, buying an estimated $57 and bringing the position to 6,410 shares worth $369K. The position accounts for 0.07% of the portfolio, ranked #260.

Silverlake Wealth Management first reported a position in BMY in Q4 2021 and has held it in 19 quarters since. The position peaked at $568K in Q2 2022. 2,524 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Silverlake Wealth Management held 6,410 shares of Bristol-Myers Squibb worth $369K as of Q2 2026.
Silverlake Wealth Management bought 1 Bristol-Myers Squibb share in Q2 2026, an estimated $57.
Bristol-Myers Squibb made up 0.07% of Silverlake Wealth Management's portfolio in Q2 2026, its #260 holding.
Silverlake Wealth Management first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 19 quarters since.
Silverlake Wealth Management's Bristol-Myers Squibb position peaked at $568K in Q2 2022.
2,524 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Silverlake Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.